Business Description
AEterna Zentaris Inc
NAICS : 325412
SIC : 3741
ISIN : CA0079754028
Description
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 221.98 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -9.71 | |||||
| Beneish M-Score | -3.03 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16.4 | |||||
| 3-Year EBITDA Growth Rate | 28.6 | |||||
| 3-Year EPS without NRI Growth Rate | 18 | |||||
| 3-Year FCF Growth Rate | 42.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.17 | |||||
| 9-Day RSI | 39.75 | |||||
| 14-Day RSI | 43.39 | |||||
| 6-1 Month Momentum % | -14.09 | |||||
| 12-1 Month Momentum % | -34.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.88 | |||||
| Quick Ratio | 7.85 | |||||
| Cash Ratio | 7.24 | |||||
| Days Inventory | 926.76 | |||||
| Days Sales Outstanding | 24.34 | |||||
| Days Payable | 6772.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -82.4 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.48 | |||||
| Operating Margin % | -261.58 | |||||
| Net Margin % | -385.35 | |||||
| ROE % | -55.6 | |||||
| ROA % | -38.58 | |||||
| ROIC % | -199.59 | |||||
| ROC (Joel Greenblatt) % | -13468.8 | |||||
| ROCE % | -44.07 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.16 | |||||
| PB Ratio | 0.43 | |||||
| Price-to-Tangible-Book | 0.43 | |||||
| EV-to-EBIT | 1.33 | |||||
| EV-to-EBITDA | 1.34 | |||||
| EV-to-Revenue | -5.27 | |||||
| EV-to-FCF | 2.06 | |||||
| Price-to-Net-Current-Asset-Value | 0.44 | |||||
| Price-to-Net-Cash | 0.51 | |||||
| Earnings Yield (Greenblatt) % | 75.19 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
AEterna Zentaris Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 8.485 | ||
| EPS (TTM) (C$) | -6.73 | ||
| Beta | 1.34 | ||
| Volatility % | 63.33 | ||
| 14-Day RSI | 43.39 | ||
| 14-Day ATR (C$) | 0.116277 | ||
| 20-Day SMA (C$) | 3.9565 | ||
| 12-1 Month Momentum % | -34.64 | ||
| 52-Week Range (C$) | 3.18 - 11.25 | ||
| Shares Outstanding (Mil) | 4.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AEterna Zentaris Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
AEterna Zentaris Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
AEterna Zentaris Inc Frequently Asked Questions
What is AEterna Zentaris Inc(TSX:AEZS)'s stock price today?
The current price of TSX:AEZS is C$3.78. The 52 week high of TSX:AEZS is C$11.25 and 52 week low is C$3.18.
When is next earnings date of AEterna Zentaris Inc(TSX:AEZS)?
The next earnings date of AEterna Zentaris Inc(TSX:AEZS) is 2023-08-03 Est..
Does AEterna Zentaris Inc(TSX:AEZS) pay dividends? If so, how much?
AEterna Zentaris Inc(TSX:AEZS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
